Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acrotech Biopharma Inc.
This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose (MTD) of belinostat when administered in combination with CHOP.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or above
Life Expectancy \> 3 months
Histologically confirmed diagnosis of PTCL
Patients with transformed CTCL eligible for CHOP regimen
Measurable disease based on Cheson 2007 criteria
Eastern Cooperative Oncology Group (ECOG) performance status \< 2
You may not be if
Known active Hepatitis B/ Hepatitis C/ HIV infection
Known, uncontrolled CNS metastases or primary CNS lymphoma
Deep vein thrombosis diagnosed within 3 months
Ongoing treatment for pre-existing cardiovascular disease
Neuropathy Grade 3 or more
Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation
Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation
Prior therapy with HDAC inhibitors (except for CTCL)
Inadequate hematological, hepatic, or renal function
Clareo Health | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
